Build a Better Process
Stock Risk Measures for Ligand Pharmaceuticals
A quantitative factor review, as of September 30, 2020.
- Company Info - Description, identity and sector data.
- Share Data - Stock earnings and key dates.
- Market Risk - Beta, size, liquidity and momentum measures.
- Financial Risk - Earnings and dividends.
Updated: October 01, 2020
See how we arrive at an overall risk score of
for LGND below.
An ad-free and cookie-free webpage by FactorPad
LGND Risk Report
Our quantitative data points are meant to provide a high-level understanding of
factors in equity risk models for Ligand Pharmaceuticals. Portfolio managers use these
models to forecast risk, optimize portfolios and review performance.
We show how LGND stock compares to 2,000+ US-based stocks, and to
peers in the Health Technology sector and Biotechnology industry.
Please do not consider this data as investment advice. Data is downloaded from
sources we deem reliable, but errors may occur.
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
- Symbol: LGND
- FactorPad FPID: f68swq
- SEC CIK: 0000886163
- Share Class FIGI: BBG001S8CH99
- Location: San Diego, CA US
- Web: http://www.ligand.com
- Employees: 115
Sector and Industry
- Sector: Health Technology
- Industry: Biotechnology
- SIC Code: 2834
Shares and Float
- Shares Outstanding: 16,078,100
- Shares Trading: 15,429,445
- Percent Trading: 96.0 %
Earnings and Dividends
- Trailing 12-month earnings: -1.32
- Next earnings date: 2020-11-05
- Dividends in last 12 months: None
- Ex-dividend date: None
Market Risk Measures
Many of the following risk metrics are standardized and transformed into
quantitative factors in institutional-level risk models.
Rankings below represent percentiles from 1 to 100, with 1 being the lowest
rating of risk.
Stocks with higher beta exhibit higher sensitivity to the ups and downs
in the market. (↑↑)
Beta: 1.14 |
Stocks with higher market capitalization often have lower risk. (↑↓)
Market Capitalization: $1,532,564,492 |
Higher average daily dollar volume over the past 30 days implies lower
liquidity risk. (↑↓)
Daily Dollar Volume: $25,471,302 |
Higher price momentum stocks, aka recent winners, equate to lower risk for many
Stock Price Change (1-Year): -2.14% |
Financial Risk Measures
Style risk factors often include measures of profitability and payout levels.
Companies with higher earnings generally provide lower risk. (↑↓)
Earnings Yield (E/P): -1.38% |
Companies with higher dividend yields, if sustaintable, are perceived to
have lower risk. (↑↓)
Dividend Yield (D/P): 0% |
LGND stock risk
LIGAND PHARMACEUTICALS stock beta
LGND risk report
LGND risk analysis
LIGAND PHARMACEUTICALS credit risk
LGND liquidity risk
LGND systematic risk
LGND specific risk
LIGAND PHARMACEUTICALS volatility
LGND financial ratio
This is a new resource, spread the word, tell a friend